[Nephrogenic systemic fibrosis and use of MR contrast media].
BACKGROUND
Nephrogenic systemic fibrosis (NSF) is a new and probably iatrogenic disorder. It was first described time in 2000 and associated with the use of gadolinium containing MR contrast media in patients with impaired renal function in 2006.


METHODS
We describe a case of NSF identified at Haukeland University Hospital and give a brief overview of the disease, based on literature retrieved from a non-systematic search.


CONCLUSIONS
NSF is a serious systemic disorder with active inflammation and fibrosis, particularly in skin, but also in other tissue such as skeletal muscle, heart and oesophagus. The condition is very difficult to treat. Awareness of the illness has led to changes in guidelines and clinical practice regarding use of gadolinium-containing contrast media in patients with renal impairment.
Christiansen
Rolf E F
RE
Medisinsk avdeling Haukeland universitetssykehus 5021 Bergen. rchr@helse-bergen.no
Sviland
Lisbet
L
Sekse
Ingegjerd
I
Svarstad
Einar
E
D000328:Adult; D003287:Contrast Media / Q000009:adverse effects*; D019786:Gadolinium DTPA / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000473:pathology; D018810:Magnetic Resonance Angiography; D008297:Male; D054989:Nephrogenic Fibrosing Dermopathy / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000276:immunology / Q000473:pathology
D003287:Contrast Media; C064925:gadodiamide; D019786:Gadolinium DTPA